TY - JOUR
T1 - Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials
T2 - a start in setting international standards
AU - Bottomley, Andrew
AU - Pe, Madeline
AU - Sloan, Jeff
AU - Basch, Ethan
AU - Bonnetain, Franck
AU - Calvert, Melanie
AU - Campbell, Alicyn
AU - Cleeland, Charles
AU - Cocks, Kim
AU - Collette, Laurence
AU - Dueck, Amylou C
AU - Devlin, Nancy
AU - Flechtner, Hans-Henning
AU - Gotay, Carolyn
AU - Greimel, Eva
AU - Griebsch, Ingolf
AU - Groenvold, Mogens
AU - Hamel, Jean-Francois
AU - King, Madeleine
AU - Kluetz, Paul G
AU - Koller, Michael
AU - Malone, Daniel C
AU - Martinelli, Francesca
AU - Mitchell, Sandra A
AU - Moinpour, Carol M
AU - Musoro, Jammbe
AU - O'Connor, Daniel
AU - Oliver, Kathy
AU - Piault-Louis, Elisabeth
AU - Piccart, Martine
AU - Pimentel, Francisco L
AU - Quinten, Chantal
AU - Reijneveld, Jaap C
AU - Schürmann, Christoph
AU - Smith, Ashley Wilder
AU - Soltys, Katherine M
AU - Taphoorn, Martin J B
AU - Velikova, Galina
AU - Coens, Corneel
AU - Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2016/11
Y1 - 2016/11
N2 - Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.
AB - Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.
U2 - 10.1016/S1470-2045(16)30510-1
DO - 10.1016/S1470-2045(16)30510-1
M3 - Journal article
C2 - 27769798
SN - 1470-2045
VL - 17
SP - e510-e514
JO - Lancet Oncology
JF - Lancet Oncology
IS - 11
ER -